Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

NeoPharm to collaborate with NCI on cytotoxic cancer ligand

April 9, 1999

Progress with AltaRex's AIT products for cancer

April 8, 1999

M-Vax cancer vaccine granted orphan drug designation

April 6, 1999

Antisoma's Theragyn granted orphan drug status in the U.S.

April 6, 1999

DSMB completes interim evaluation of Maxamine phase III clinical trials

April 1, 1999

Reanalysis of data attributes greater efficacy to Multikine

March 30, 1999

Procyon receives Canadian patent for PSP94

March 30, 1999

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

March 29, 1999

Maxim allowed additional U.S. patent for Maxamine technology

March 22, 1999

Mouse study provides preliminary indications of the antitumor efficacy of AR-209

March 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...